[1] |
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013, 158(11): 825-830.
doi: 10.7326/0003-4819-158-11-201306040-00007
pmid: 23732715
|
[2] |
Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016[J]. Kidney Int, 2018, 94(3): 567-581.
doi: 10.1016/j.kint.2018.04.011
URL
|
[3] |
Bökenkamp A. Proteinuria-take a closer look![J]. Pediatric nephrology (Berlin, Germany), 2020, 35(4): 533-541.
doi: 10.1007/s00467-019-04454-w
URL
|
[4] |
Huang Z, Wen Q, Zhou SF, et al. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome[J]. Cytokine, 2008, 42(2): 222-233.
doi: S1043-4666(08)00040-9
pmid: 18362077
|
[5] |
Li B, Chen K, Wang J, et al. Low-grade albuminuria is associated with high cardiovascular risk in CVD-free and normoalbuminuric Chinese adults: Results from the REACTION study[J]. J Diabetes, 2021, 13(8): 648-660.
doi: 10.1111/1753-0407.13152
pmid: 33389816
|
[6] |
Darlington O, Dickerson C, Evans M, et al. Costs and healthcare resource use associated with risk of cardiovascular morbidity in patients with chronic kidney disease: Evidence from a systematic literature review[J]. Adv Ther, 2021, 38(2): 994-1010.
doi: 10.1007/s12325-020-01607-4
pmid: 33432542
|
[7] |
Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects[J]. Physiol Rev, 2016, 96(1): 365-408.
doi: 10.1152/physrev.00014.2015
pmid: 26681795
|
[8] |
Jiang S, Zhang H, Li X, et al. Vitamin D/VDR attenuate cisplatin-induced AKI by down-regulating NLRP3/Caspase-1/GSDMD pyroptosis pathway[J]. J Steroid Biochem Mol Biol, 2021, 206: 105789.
doi: 10.1016/j.jsbmb.2020.105789
URL
|
[9] |
Molina P, Górriz JL, Molina MD, et al. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled study[J]. Nephrol Dial Transplant, 2014, 29(1): 97-109.
doi: 10.1093/ndt/gft360
URL
|
[10] |
Xu L, Wan X, Huang Z, et al. Impact of vitamin D on chronic kidney diseases in non-dialysis patients: A meta-analysis of randomized controlled trials[J]. PLoS One, 2013, 8(4): e61387.
doi: 10.1371/journal.pone.0061387
URL
|
[11] |
Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial[J]. Hypertension, 2008, 52(2): 249-255.
doi: 10.1161/HYPERTENSIONAHA.108.113159
pmid: 18606901
|
[12] |
Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial[J]. Am J Kidney Dis, 2009, 54(4): 647-652.
doi: 10.1053/j.ajkd.2009.04.036
pmid: 19596163
|
[13] |
de Zeeuw D, Agarwal R, AMDahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes(VITAL study): A randomised controlled trial[J]. Lancet, 2010, 376(9752): 1543-1551.
doi: 10.1016/S0140-6736(10)61032-X
pmid: 21055801
|
[14] |
Liu LJ, Lv JC, Shi SF, et al. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: A randomized controlled trial[J]. Am J Kidney Dis, 2012, 59(1): 67-74.
doi: 10.1053/j.ajkd.2011.09.014
pmid: 22019331
|
[15] |
Molina P, Górriz JL, Molina MD, et al. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled study[J]. Nephrol Dial Transplant, 2014, 29(1): 97-109.
doi: 10.1093/ndt/gft360
URL
|
[16] |
殷勋, 水光兴, 桑栋, 等. 1, 25(OH)2D3延缓慢性肾衰竭进展的临床随机对照研究[J]. 中国中西医结合肾病杂志, 2014, 15(1):54-56.
|
[17] |
Wu CC, Liao MT, Hsiao PJ, et al. Antiproteinuria effect of calcitriol in patients with chronic kidney disease and vitamin d deficiency: A randomized controlled study[J]. J Ren Nutr, 2020, 30(3):200-207.
doi: 10.1053/j.jrn.2019.09.001
URL
|
[18] |
Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review[J]. JAMA, 2019, 322(13): 1294-1304.
doi: 10.1001/jama.2019.14745
pmid: 31573641
|
[19] |
Sharma S, Smyth B. From proteinuria to fibrosis: An update on pathophysiology and treatment options[J]. Kidney Blood Press Res, 2021, 46(4): 411-420.
doi: 10.1159/000516911
URL
|
[20] |
Liu D, Lv LL. New understanding on the role of proteinuria in progression of chronic kidney disease[J]. Adv Exp Med Biol, 2019, 1165: 487-500.
doi: 10.1007/978-981-13-8871-2_24
pmid: 31399981
|
[21] |
Canney M, Barbour SJ, Zheng Y, et al. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy[J]. J Am Soc Nephrol, 2021, 32(2): 436-447.
doi: 10.1681/ASN.2020030349
pmid: 33514642
|
[22] |
Liu BC, Tang TT, Lv LL, et al. Renal tubule injury: A driving force toward chronic kidney disease[J]. Kidney Int, 2018, 93(3): 568-579.
doi: 10.1016/j.kint.2017.09.033
URL
|
[23] |
Sanz AB, Ramos AM, Soler MJ, et al. Advances in understanding the role of angiotensin-regulated proteins in kidney diseases[J]. Expert Rev Proteomics, 2019, 16(1): 77-92.
doi: 10.1080/14789450.2018.1545577
URL
|
[24] |
Tuttle KR, Brosius FC 3rd, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation[J]. AAm J Kidney Dis, 2021, 77(1): 94-109.
|
[25] |
Broek MVD, Smeets B, Schreuder MF, et al. The podocyte as a direct target of glucocorticoids in nephrotic syndrome[J]. Nephrol Dial Transplant, 2022, 37(10):1808-1815.
doi: 10.1093/ndt/gfab016
URL
|
[26] |
Martínez-Arias L, Panizo S, Alonso-Montes C, et al. Effects of calcitriol and paricalcitol on renal fibrosis in CKD[J]. Nephrol Dial Transplant, 2021, 36(5): 793-803.
doi: 10.1093/ndt/gfaa373
URL
|
[27] |
Namir Y, Cohen MJ, Haviv YS, et al. Vitamin D levels, vitamin D supplementation, and prognosis in patients with chronic kidney disease[J]. Clin Nephrol, 2016, 86(10): 165-1674.
doi: 10.5414/CN108796
URL
|
[28] |
Manson JE, Cook NR, LeeI M, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease[J]. N Engl J Med, 2019, 380(1): 33-44.
doi: 10.1056/NEJMoa1809944
URL
|